-+ 0.00%
-+ 0.00%
-+ 0.00%

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Barchart·08/05/2026 06:00:00
Listen to the news

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

KT-621 Phase 3 trials in AD planned to initiate by mid-2027

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.